SCHEMBL5682245

SCHEMBL5682245

O=P(O)(O)OP(=O)(O)Oc1ccc2ccc3cccc4ccc1c2c34

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 5/20 0.37
HPGD P15428 5/20 0.37
HSD17B10 Q99714 4/20 0.37
CYP3A4 P08684 2/20 0.37
TSHR P16473 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KDM4E B2RXH2 2/20 0.36
MAPT P10636 1/20 0.36
INPPL1 O15357 2/20 0.36
INPP5A Q14642 2/20 0.36
INPP5B P32019 1/20 0.36
GPR84 Q9NQS5 1/20 0.36
CYP1A2 P05177 4/20 0.35
ERBB2 P04626 1/20 0.35
FYN P06241 1/20 0.35
MAOA P21397 1/20 0.35
ACHE P22303 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21969523 0.90 GPR84 (0.42) KMT2AMEN1ALDH1A1HPGDHSD17B10
SCHEMBL4521607 0.87 INPPL1 (0.48) KMT2AMEN1ALDH1A1HPGDHSD17B10
SCHEMBL27745872 0.84 ALDH1A1 (0.41) KMT2AMEN1ALDH1A1HPGDHSD17B10
SCHEMBL27692904 0.81 KMT2A (0.35) KMT2AMEN1ALDH1A1HPGDHSD17B10
SCHEMBL30332098 0.80 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1HPGDHSD17B10
SCHEMBL6251330 0.79 HTT (0.46) KMT2AMEN1ALDH1A1HPGDHSD17B10
Pyrene SCHEMBL21437358 0.77 ALDH1A1 (0.52) KMT2AMEN1ALDH1A1HPGDHSD17B10
SCHEMBL27947558 0.77 MAPT (0.43) KMT2AMEN1ALDH1A1HPGDHSD17B10
SCHEMBL9973244 0.77 ALDH1A1 (0.46) KMT2AMEN1ALDH1A1HPGDHSD17B10
SCHEMBL30935962 0.74 MAPT (0.39) KMT2AMEN1ALDH1A1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092406-A1 FUNCTIONALLY-ENHANCED XNA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-03-20 US disclosed
EP-4377463-A1 FUNCTIONALLY-ENHANCED XNA The Regents of the University of California (US) 2024-06-05 EP disclosed
US-11858953-B2 Compositions and methods for synthesis of phosphorylated molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-01-02 US disclosed
WO-2023009898-A1 FUNCTIONALLY-ENHANCED XNA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-02-02 WO disclosed
US-20210332070-A1 Compositions and Methods for Synthesis of Phosphorylated Molecules UNIV CALIFORNIA (US) 2021-10-28 US disclosed
US-11021497-B2 Compositions and methods for synthesis of phosphorylated molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-06-01 US disclosed
US-20200239500-A1 Compositions and Methods for Synthesis of Phosphorylated Molecules THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-07-30 US disclosed
WO-2019195494-A1 COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-10-10 WO disclosed
EP-1501505-B1 USE OF (3-(2-ETHYLPHENYL)-5-METHOXYPHENYL)-1H- 1,2,4 -TRIAZOLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES SIGMA TAU IND FARMACEUTI (IT) 2006-01-18 EP disclosed
US-20050026980-A1 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-[1,2,4]-triazole for the treatment of autoimmune diseases SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2005-02-03 US disclosed
EP-1501505-A1 USE OF (3-(2-ETHYLPHENYL)-5-METHOXYPHENYL)-1H- 1,2,4 -T RIAZOLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 2005-02-02 EP disclosed
US-6797722-B2 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2004-09-28 US disclosed
WO-2003092681-A1 USE OF (3-(2-ETHYLPHENYL)-5-METHOXYPHENYL)-1H-[1,2,4]-TRIAZOLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2003-11-13 WO disclosed
US-20030207931-A1 USE OF 3-(2-ETHYLPHENYL)-5-(3-METHOXYPHENYL)-1H-1,2,4-TRIAZOLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858953-B2 Compositions and methods for synthesis of phosphorylated molecules PIK3CA, CHAMP1, TYMP KMT2A 2972/4885MEN1 2132/4885ALDH1A1 4371/4885
US-20200239500-A1 Compositions and Methods for Synthesis of Phosphorylated Molecules PIK3CA, CHAMP1, TYMP KMT2A 2972/4885MEN1 2132/4885ALDH1A1 4371/4885
US-11021497-B2 Compositions and methods for synthesis of phosphorylated molecules PIK3CA, CHAMP1, TYMP KMT2A 2972/4885MEN1 2132/4885ALDH1A1 4371/4885
US-20210332070-A1 Compositions and Methods for Synthesis of Phosphorylated Molecules PIK3CA, CHAMP1, TYMP KMT2A 2972/4885MEN1 2132/4885ALDH1A1 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.